View in EDS

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Saved in:
Bibliographic Details
Title: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.
Authors: Borcoman E; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France.; Translational Immunotherapy Team, Translational Research Department, Institut Curie, Paris, France.; Université Paris Sciences Lettres (PSL), Paris, France., Cabarrou B; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, Toulouse, France., Francisco M; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France.; Paris-Saclay University, Paris, France., Bigot F; Institut de Cancérologie de l'Ouest, Angers, France., Ghiringhelli F; Centre Georges-François Leclerc, Dijon, France., Vansteene D; Institut de Cancérologie de l'Ouest, Saint-Herblain, France., Legrand F; Unicancer, Paris, France., Halladjian M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Dupain C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Le Saux O; Medical Oncology, Centre Léon Berard, Lyon, France., Coutzac C; Medical Oncology, Centre Léon Berard, Lyon, France., Borel C; Centre Paul Strauss, Strasbourg, France., Chaltiel R; Institut Godinot, Reims, France., You B; Medical Oncology, CITOHL, EPSILYON, IC-HCL, Lyon University Hospital (HCL), University Lyon 1, Lyon, France., Gomez-Roca C; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France., Cousin S; Institut Bergonié, Bordeaux, France., Coquan E; Centre François Baclesse, Caen, France., Lambert A; Institut de Cancerologie de Lorraine, Vandœuvre-Lès-Nancy, France., Saada-Bouzid E; Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.; Laboratory of Translational Research in Oncology, Cote D'Azur University, Nice, France., Durando X; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France., Saint-Ghislain M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Frige G; Experimental Oncology, Instituto Europeo di Oncologia, Milan, Italy., Guerini-Rocco E; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, European University of Milan, Milan, Italy., Tonini MM; Translational Medicine Operations Hub, Luxembourg Institute of Health, Strassen, Luxembourg., Bièche I; Department of Genetics, Institut Curie, Paris, France., Castel-Ajgal Z; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Marret G; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Sablin MP; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Jeannot E; Department of Pathology, Institut Curie, Paris, France., Andre F; Gustave Roussy, Villejuif, France., Filleron T; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, Toulouse, France., Jimenez M; Unicancer, Paris, France., Mazzarella L; Laboratory of Translational Oncology, European Institute of Oncology IRCCS, Milano, Italy.; Division of Gatrointestinal Oncology, European Institute of Oncology IRCCS, Milano, Italy.; Division of Advanced Molecular Diagnostics (DIMA), European Institute of Oncology IRCCS, Milano, Italy., Servant N; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France., Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France. christophe.letourneau@curie.fr.; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France. christophe.letourneau@curie.fr.; Paris-Saclay University, Paris, France. christophe.letourneau@curie.fr.
Source: Nature cancer [Nat Cancer] 2025 Aug; Vol. 6 (8), pp. 1370-1383. Date of Electronic Publication: 2025 Jun 30.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40588522
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Borcoman+E%22">Borcoman E</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.; INSERM U932, Immunity and Cancer, Institut Curie, Paris, France.; Translational Immunotherapy Team, Translational Research Department, Institut Curie, Paris, France.; Université Paris Sciences Lettres (PSL), Paris, France.<br /><searchLink fieldCode="AU" term="%22Cabarrou+B%22">Cabarrou B</searchLink>; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Francisco+M%22">Francisco M</searchLink>; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France.; Paris-Saclay University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bigot+F%22">Bigot F</searchLink>; Institut de Cancérologie de l'Ouest, Angers, France.<br /><searchLink fieldCode="AU" term="%22Ghiringhelli+F%22">Ghiringhelli F</searchLink>; Centre Georges-François Leclerc, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Vansteene+D%22">Vansteene D</searchLink>; Institut de Cancérologie de l'Ouest, Saint-Herblain, France.<br /><searchLink fieldCode="AU" term="%22Legrand+F%22">Legrand F</searchLink>; Unicancer, Paris, France.<br /><searchLink fieldCode="AU" term="%22Halladjian+M%22">Halladjian M</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Dupain+C%22">Dupain C</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Le+Saux+O%22">Le Saux O</searchLink>; Medical Oncology, Centre Léon Berard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Coutzac+C%22">Coutzac C</searchLink>; Medical Oncology, Centre Léon Berard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Borel+C%22">Borel C</searchLink>; Centre Paul Strauss, Strasbourg, France.<br /><searchLink fieldCode="AU" term="%22Chaltiel+R%22">Chaltiel R</searchLink>; Institut Godinot, Reims, France.<br /><searchLink fieldCode="AU" term="%22You+B%22">You B</searchLink>; Medical Oncology, CITOHL, EPSILYON, IC-HCL, Lyon University Hospital (HCL), University Lyon 1, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Gomez-Roca+C%22">Gomez-Roca C</searchLink>; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Cousin+S%22">Cousin S</searchLink>; Institut Bergonié, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Coquan+E%22">Coquan E</searchLink>; Centre François Baclesse, Caen, France.<br /><searchLink fieldCode="AU" term="%22Lambert+A%22">Lambert A</searchLink>; Institut de Cancerologie de Lorraine, Vandœuvre-Lès-Nancy, France.<br /><searchLink fieldCode="AU" term="%22Saada-Bouzid+E%22">Saada-Bouzid E</searchLink>; Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.; Laboratory of Translational Research in Oncology, Cote D'Azur University, Nice, France.<br /><searchLink fieldCode="AU" term="%22Durando+X%22">Durando X</searchLink>; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.<br /><searchLink fieldCode="AU" term="%22Saint-Ghislain+M%22">Saint-Ghislain M</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Frige+G%22">Frige G</searchLink>; Experimental Oncology, Instituto Europeo di Oncologia, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Guerini-Rocco+E%22">Guerini-Rocco E</searchLink>; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, European University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Tonini+MM%22">Tonini MM</searchLink>; Translational Medicine Operations Hub, Luxembourg Institute of Health, Strassen, Luxembourg.<br /><searchLink fieldCode="AU" term="%22Bièche+I%22">Bièche I</searchLink>; Department of Genetics, Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Castel-Ajgal+Z%22">Castel-Ajgal Z</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Marret+G%22">Marret G</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sablin+MP%22">Sablin MP</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Jeannot+E%22">Jeannot E</searchLink>; Department of Pathology, Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Andre+F%22">Andre F</searchLink>; Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Filleron+T%22">Filleron T</searchLink>; Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Jimenez+M%22">Jimenez M</searchLink>; Unicancer, Paris, France.<br /><searchLink fieldCode="AU" term="%22Mazzarella+L%22">Mazzarella L</searchLink>; Laboratory of Translational Oncology, European Institute of Oncology IRCCS, Milano, Italy.; Division of Gatrointestinal Oncology, European Institute of Oncology IRCCS, Milano, Italy.; Division of Advanced Molecular Diagnostics (DIMA), European Institute of Oncology IRCCS, Milano, Italy.<br /><searchLink fieldCode="AU" term="%22Servant+N%22">Servant N</searchLink>; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France.<br /><searchLink fieldCode="AU" term="%22Kamal+M%22">Kamal M</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Le+Tourneau+C%22">Le Tourneau C</searchLink>; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France. christophe.letourneau@curie.fr.; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France. christophe.letourneau@curie.fr.; Paris-Saclay University, Paris, France. christophe.letourneau@curie.fr.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101761119%22">Nature cancer</searchLink> [Nat Cancer] 2025 Aug; Vol. 6 (8), pp. 1370-1383. <i>Date of Electronic Publication: </i>2025 Jun 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101761119 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2662-1347 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226621347%22">26621347 </searchLink><i>NLM ISO Abbreviation: </i>Nat Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40588522
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s43018-025-01004-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1370
    Titles:
      – TitleFull: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Borcoman E
      – PersonEntity:
          Name:
            NameFull: Cabarrou B
      – PersonEntity:
          Name:
            NameFull: Francisco M
      – PersonEntity:
          Name:
            NameFull: Bigot F
      – PersonEntity:
          Name:
            NameFull: Ghiringhelli F
      – PersonEntity:
          Name:
            NameFull: Vansteene D
      – PersonEntity:
          Name:
            NameFull: Legrand F
      – PersonEntity:
          Name:
            NameFull: Halladjian M
      – PersonEntity:
          Name:
            NameFull: Dupain C
      – PersonEntity:
          Name:
            NameFull: Le Saux O
      – PersonEntity:
          Name:
            NameFull: Coutzac C
      – PersonEntity:
          Name:
            NameFull: Borel C
      – PersonEntity:
          Name:
            NameFull: Chaltiel R
      – PersonEntity:
          Name:
            NameFull: You B
      – PersonEntity:
          Name:
            NameFull: Gomez-Roca C
      – PersonEntity:
          Name:
            NameFull: Cousin S
      – PersonEntity:
          Name:
            NameFull: Coquan E
      – PersonEntity:
          Name:
            NameFull: Lambert A
      – PersonEntity:
          Name:
            NameFull: Saada-Bouzid E
      – PersonEntity:
          Name:
            NameFull: Durando X
      – PersonEntity:
          Name:
            NameFull: Saint-Ghislain M
      – PersonEntity:
          Name:
            NameFull: Frige G
      – PersonEntity:
          Name:
            NameFull: Guerini-Rocco E
      – PersonEntity:
          Name:
            NameFull: Tonini MM
      – PersonEntity:
          Name:
            NameFull: Bièche I
      – PersonEntity:
          Name:
            NameFull: Castel-Ajgal Z
      – PersonEntity:
          Name:
            NameFull: Marret G
      – PersonEntity:
          Name:
            NameFull: Sablin MP
      – PersonEntity:
          Name:
            NameFull: Jeannot E
      – PersonEntity:
          Name:
            NameFull: Andre F
      – PersonEntity:
          Name:
            NameFull: Filleron T
      – PersonEntity:
          Name:
            NameFull: Jimenez M
      – PersonEntity:
          Name:
            NameFull: Mazzarella L
      – PersonEntity:
          Name:
            NameFull: Servant N
      – PersonEntity:
          Name:
            NameFull: Kamal M
      – PersonEntity:
          Name:
            NameFull: Le Tourneau C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2662-1347
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Nature cancer
              Type: main
ResultId 1